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Current human immunodeficiency virus (HIV) vaccine approaches emphasize prime boost
strategies comprising multiple doses of DNA vaccine and recombinant viral vectors. We are
developing a protein-based approach that directly harnesses principles for generating T cell
immunity. Vaccine is delivered to maturing dendritic cells in lymphoid tissue by engineering
protein antigen into an antibody to DEC-205, a receptor for antigen presentation. Here we
characterize the CD4+ T cell immune response to HIV gag and compare efficacy with other
vaccine strategies in a single dose. DEC-205–targeted HIV gag p24 or p41 induces stronger
CD4+ T cell immunity relative to high doses of gag protein, HIV gag plasmid DNA, or
recombinant adenovirus-gag. High frequencies of interferon (IFN)-𝛄– and interleukin 2–
producing CD4+ T cells are elicited, including double cytokine-producing cells. In addition,
the response is broad because the primed mice respond to an array of peptides in different
major histocompatibility complex haplotypes. Long-lived T cell memory is observed. After
subcutaneous vaccination, CD4+ and IFN-𝛄–dependent protection develops to a challenge
with recombinant vaccinia-gag virus at a mucosal surface, the airway. We suggest that a
DEC-targeted vaccine, in part because of an unusually strong and protective CD4+ T cell
response, will improve vaccine efficacy as a stand-alone approach or with other modalities.
CORRESPONDENCE
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Vaccine development for major global infectious diseases will likely require strategies that
induce strong T cell–mediated immunity, which
is implicated in resistance to infections like
HIV/AIDS, malaria, tuberculosis, and human
papilloma and Epstein Barr viruses (1–5). One
critical element of T cell–mediated immunity
is the CD4+ helper T cell. These T cells are
able to produce high levels of IFN-γ, exert cytolytic activity on MHC class II–bearing targets,
and help other elements of the immune response,
such as antibody formation and CD8+ cytolytic
killer cells including memory (6). HIV-infected
patients who have a better clinical course and
are long-term nonprogressors tend to have
stronger CD4+ T cell responses to the virus (7, 8),
and HIV-specific CD4+ T cells are able to promote the function of HIV-specific CD8+ T cells
The online version of this article contains supplemental material.
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in vitro (9). It is therefore important to identify
and harness principles of immune function that
would improve CD4+ T cell immunity to HIV
vaccines (10, 11).
Prior studies have used tissue culture systems, as well as adoptive transfer of DCs into
animals and people, to show that these cells
induce strong T cell–mediated immunity (for
review see references 12–17). For example,
isolated DCs are able to initiate CD4+ helper
T cell responses in culture (18) and after reinfusion into mice (19). When human (20) or mouse
(21) DCs are loaded with antigen ex vivo and
reinfused, the DCs expand antigen-specific
helper cells that primarily produce IFN-γ and
not IL-4; i.e., a Th1 type of CD4+ T cell that is
thought to be valuable in host defense against
viral infection (2, 3).
We have been developing a different approach to study the function of DCs directly in
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1Laboratory

and peptide (AMQMLKETI, p24 197–205, 2 μg/ml), HIV gag p24 peptide
pools (2 μg/ml), or medium alone for 2 d. IFN-γ secretion was evaluated
by ELISPOT. (B) As in A, but immunization of BALB/c mice with graded
doses of anti–DEC-p24 and a maturation stimulus. Data are representative of two to four similar experiments with two mice pooled in
each experiment.

lymphoid tissues in situ and to harness the immunizing capacities of DCs in vaccine design. The approach is to deliver
antigens within antibodies that selectively deliver vaccine
proteins to DCs in lymphoid tissues. Our first experiments
have targeted DEC-205/CD205, an endocytic receptor (22,
23) that was originally termed the NLDC-145 antigen and is
expressed at high levels on DCs (24), particularly a subset of
DCs, in lymphoid tissues (25). Although DEC-205 is expressed at high levels on several epithelia, and at low levels on
many leukocytes (26, 27), the injected antibody primarily
binds to DCs in the T cell areas (28). When antigens are incorporated into the anti–DEC-205 mAb, there is efficient
antigen presentation on both MHC class I and II products;
i.e., low doses of the targeted antigen relative to nontargeted
antigen are required to present antigen in vivo (28–31). It is
important to extend the concept of directed delivery of antigen to DCs in situ to more clinically relevant antigens, to additional immune readouts, and to comparisons with other
vaccine modalities.
In our prior studies of antigen presentation by DCs in
situ, we have chemically coupled the protein OVA to the
anti-DEC antibody, or we have engineered the cDNA of the
heavy chain of the antibody to express sequences for antigenic

peptides in frame at its carboxy terminus. We regard the
latter engineering method to be preferable in that fusion antibodies can be expressed that reliably contain a single copy
of the antigen on every heavy chain. For immunization to
take place after injection of antigen within anti–DEC-205
mAb, we also observed that it is necessary to overcome the
normal capacity of the DEC-205+ DCs in situ to induce
peripheral tolerance. This can be achieved by administering
agonistic anti-CD40 mAb as a stimulus for the maturation of
DCs in vivo (28–30). Using OVA as an antigen, we have
shown that the combination of DC targeting and a maturation stimulus improves CD4+ and CD8+ T cell responses
in naive mice, as assessed with single MHC class I and II
binding peptides (30).
Here we have engineered the p24 and p41 proteins from
HIV gag into the heavy chain of anti–DEC-205 and studied
the immune responses to the fusion mAb along with a maturation stimulus. We find that DC targeting with an anti-DEC205–HIV gag fusion mAb vaccine induces CD4+ T cell
immunity of a quantity and quality that has not been seen before with safe vaccines. The CD4+ T cell response to a single
dose of vaccine, as assessed by IFN-γ and IL-2 production, is
much greater than that observed with plasmid gag DNA and
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Figure 1. Immunization of T cells with one dose of anti–DEC-p24
fusion mAb vaccine. (A) BALB/c mice were injected i.p. with PBS, maturation stimulus alone (25 μg αCD40 mAb and 50 μg poly IC), 5 μg control Ig-p24 or anti–DEC-p24 mAbs and maturation stimulus, and 5 μg
anti–DEC-p24 without maturation stimulus. After 17 d, splenic CD8+
T cells (top) or CD4+ T cells (bottom) were restimulated with CD11c+ DCs
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recombinant adenoviral gag vaccination, although these other
approaches produce equal or more CD8+ IFN-γ–producing
T cells. The immune response to anti–DEC-HIV gag comprises several potentially valuable features, including a broad
response to many peptides in different MHC backgrounds as
well as CD4-dependent protection at mucosal surfaces.

JEM VOL. 203, March 20, 2006

Figure 2. Strong CD4+ T cell responses to a single dose of anti–
DEC-p24 fusion mAb vaccine. (A) BALB/c mice were immunized s.c.
with graded doses of anti–DEC-p24 or control Ig-p24 mAbs and maturation stimulus. 19 d later, we assessed the percentage of IFN-γ+ CD4+ cells
in gated CD3+ splenic T cells using gag p24 peptide pools. One of three
similar experiments with two mice pooled in each experiment is shown.
(B) As in A, but several experiments showing responses to 5 μg anti–DECp24 or control Ig-p24 mAbs with maturation stimulus given either s.c. or
i.p. to BALB/c mice. Background activity (<0.1%) of nonvaccinated mice
boosted with the HIV gag p24 peptide pools was subtracted from the
percentage of IFN-γ+ CD4+ cells. Each point represents two mice pooled
in each experiment. (C) BALB/c or C57BL/6 mice were treated s.c. with PBS
or 2 and 5 μg anti–DEC-p24 or control Ig-p24 mAbs, respectively, each
with maturation stimulus. IFN-γ and IL-2 production was monitored at
19 d. Numbers are the percentage of CD4+ cells producing cytokines to
HIV gag p24 peptide pool 3 in BALB/c or pool 1 in C57BL/6 mice. These
experiments were repeated two to four times with similar results.
(D) Comparison of immune responses of wild-type and DEC-205−/− mice
to 3 μg anti–DEC-p24 vaccine and maturation stimulus. IFN-γ secretion
in response to HIV gag p24 peptide pools by CD4+ splenocytes as in A.
Background frequencies (vaccinated mice boosted in medium only) were
<0.01% in the top right quadrants. Data are representative of two
similar experiments.
609
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RESULTS
DEC-205 targeting of HIV gag p24 enhances antigen
presentation in vivo
To harness the antigen processing (32) and immunizing
functions of DCs (16, 17) within intact lymphoid organs, we
cloned HIV gag p24 protein in frame with the carboxyl terminus of the heavy chain of an mAb to mouse DEC-205, an
endocytic receptor for antigen presentation (22, 23). We also
engineered the heavy chain of a control mAb that does not
react with DCs. In prior studies, sequences for peptides were
fused to the heavy chain (28, 31), but here we introduced
gag protein (Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20052005/DC1). The fusion mAbs
were successfully expressed and contained heavy chains of
75 kD as opposed to 50 kD for unmodified mouse
IgG1 (Fig. S1). Relative to the original anti–DEC-205 mAb,
these fusion mAbs bound identically to DEC-205 transfectants (not depicted).
To use fusion mAbs as vaccines, we needed to overcome
the capacity of DEC-205–bearing DCs to induce tolerance
(28, 29, 31). To do so, we injected a stimulus for DC maturation together with the engineered mAb into 7–8-wk-old
mice. We used a combination of the TLR3 ligand poly IC
and an agonistic anti-CD40 mAb. In preliminary experiments,
poly IC by itself did not lead to a primary immune response to
anti–DEC-p24, but in keeping with prior observations (33),
the combination of a TLR ligand and anti-CD40 did elicit
stronger immunity. To detect T cell immunity, we used a
library of 15-mer “mimetope” peptides staggered every 4 aa
along the gag p24 sequence (34, 35). This library was divided
into five peptide pools (each containing 9–12 peptides), each
of which was used to recall IFN-γ secretion in spleen cells
from mice vaccinated with a single dose of anti–DEC-p24.
In initial experiments, an ELISPOT assay showed that
BALB/c mice made T cell responses after vaccination with
the combination of fusion mAb and maturation stimulus, but
not with either alone (Fig. 1 A). The CD8+ T cell response
was directed to peptides in p24 pool 2 (Fig. 1 A, top, white
bar), which contained a previously defined gag 197–205 peptide sequence presented on H-2Kd (Fig. 1 A, top, black bar;
reference 36). In addition, CD4+ T cell responses were noted
to peptides in p24 pools 1 and 3 (Fig. 1 A, bottom), and these
involved IFN-γ production but no detectable IL-4 (not
depicted). Interestingly, we had to administer higher doses of
fusion mAb to elicit a CD8+ T cell response than a CD4+ T
cell response. The former response to p24 pool 2 peptides
was increasing when the dose of mAb was increased from
5 to 20 μg/mouse (Fig. 1 B, top), whereas the helper responses to p24 pools 1 and 3 peptides could plateau between

1 and 5 μg/mouse (and some responses began to be detected
with the control Ig-p24 vaccine; Fig. 1 B, bottom). We then
turned to intracellular cytokine staining to monitor immunization because the response to a single dose of vaccine was
large enough to be detected by this approach, and we concentrated our studies on the CD4+ T cell response because
helper cells energize many components of immunity.

Figure 3. Enhanced efficacy of anti–DEC-p24 plus anti-CD40/poly
IC relative to DNA and nontargeted protein vaccines. (A) C57BL/6
mice were injected s.c. with maturation stimulus and the proteins indicated above each panel. IFN-γ secretion was evaluated after 18 d in the
spleen by intracellular cytokine staining as the percentage of IFN-γ CD4+
cells among CD3+ lymphocytes in response to HIV gag p24 peptide pool 4.
Data are one of two to four similar experiments. (B) BALB/c mice were
injected with 2 μg anti–DEC-p24 s.c. plus maturation stimulus, one or
two doses of 50 μg DNA encoding HIV gag p24 protein i.m., or PBS. IFN-γ
secretion in response to HIV gag p24 peptide pool 3 was evaluated as in A.
Data shown are one of two to four similar experiments. (C) BALB/c mice
were immunized i.p. with 5 μg anti–DEC-p24 or control Ig-p24 antibodies
plus maturation stimulus, two doses of 50 μg DNA encoding HIV gag p24
protein i.m., or PBS. IFN-γ secretion was evaluated as in A, but the response to HIV gag p24 peptide pool 2 (containing a dominant peptide
presented on MHC class I) and p24 pool 3 (containing a peptide presented on MHC class II) are shown for T cells directly stained for CD8
expression. Data shown are from one of two similar experiments.
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Anti–DEC-p24 immunization enhances CD4+ T cell
immunity relative to other immunization approaches
We compared the response to DC-targeted HIV gag p24
with other modes of immunization. When we injected 1–50
μg of soluble HIV p41 protein with anti-CD40 and poly
IC maturation, or the combination of HIV protein with unconjugated anti–DEC-205 mAb, the immune responses were
weak compared with DC-targeted HIV gag p24 with the
same maturation stimulus (Fig. 3 A). A single dose of HIV
protein likewise did not induce immunity by these assays
when we tested other standard adjuvants, complete Freund’s
adjuvant and alum (not depicted). We then tested plasmid
DNA vaccines, which are currently in trials for immunization of healthy volunteers (37–39). The CD4+ T cell response to one or two injections of 50 μg of a gag p24 DNA
vaccine was either weak or undetectable for each of the p24
peptide pools (e.g., p24 pool 3 in Fig. 3 B). The response was
likewise weak if the mice were injected with anti-CD40 and
poly IC along with the DNA vaccine (not depicted). In contrast, the DNA vaccine did elicit a CD8+ T cell response to a
dominant gag peptide for BALB/c mice in p24 peptide pool 2,
comparable to that observed with the DC-targeted p24 protein vaccine (Fig. 3 C, top right quadrants). However, we
ANTI–DENDRITIC CELL HIV FUSION ANTIBODY VACCINE | Trumpfheller et al.
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A strong IL-2– and IFN-𝛄–producing CD4+ T cell response
to anti–DEC-p24
To establish the efficiency of DEC-205 targeting, we immunized BALB/c mice with increasing doses of anti–DEC-p24
mAb plus maturation stimuli or control Ig-p24. Targeting via
DEC-205 was at least 100 times more effective at initiating
IFN-γ–producing CD4+ T cell immunity (Fig. 2 A, compare filled and open symbols) than control Ig-p24 or soluble
gag protein (see below). When we assessed the route of injection, the i.p. route led to slightly higher immune responses
than the s.c. route (Fig. 2 B, compare filled squares to circles),
possibly because the delivery of the injected antibody solution was more reliable in the former case. When we monitored both IFN-γ and IL-2 production in BALB/c and
C57BL/6 mice, the majority of primed cells made both cytokines (Fig. 2 C, top right quadrants), whereas lower frequencies made only one of the cytokines. We also tested
DEC-205−/− mice to show that DEC-205 was essential for
immunization (Fig. 2 D). Thus, the use of anti–DEC-205
mAb targeting greatly increases the efficiency with which
protein antigens elicit T cell immunity, and when given as a
single dose together with stimuli for DC maturation, the frequency of primed CD4+ T cells is high.
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Table I. CD4+ and CD8+ T cell responses to HIV gag p24 in BALB/c mice after a single immunization via anti−DEC-205 antibody
or recombinant adenovirus
Experiment

1
2

IFN-𝛄+ cells/104 CD4+ T cells
(no peptide/pool 3 restimulation)

Spleen

A
B
A
B

IFN-𝛄+ cells/104 CD8+ T cells
(no peptide/pool 2 restimulation)

No
vaccine

Control
Ig p24

anti-DEC
p24

adeno
5 × 105

adeno
2 × 107

No
vaccine

Control
Ig p24

anti-DEC
p24

adeno
5 × 105

adeno
2 × 107

8/5
4/5
9/15
2/3

2/4
3.4
13/19
2/5

2/101
7/50
16/125
4/72

4/14
6/7
14/26
3/7

ND
ND
16/24
3/12

1/14
8/8
16/14
3/4

4/9
6/11
16/14
2/4

4/13
11/14
15/17
5/17

7/40
14/74
15/59
2/160

ND
ND
13/326
2/432

could not detect IFN-γ–producing CD4+ T cell responses
to two doses of DNA vaccine by intracellular cytokine staining relative to DC-targeted HIV gag p24 (Fig. 3 C, compare
IFN-γ production by CD8− cells in the top left quadrants in
the DNA- and anti–DEC-p24–vaccinated mice). Lastly, we
tested a recombinant adenovirus-gag vaccine. A single dose
i.m. induced clear-cut CD8+ T cell responses, clearly greater
than anti–DEC-p24, but the CD4+ T cell responses remained
low relative to anti–DEC-p24 (Table I and Fig. S2, available
at http://www.jem.org/cgi/content/full/jem.20052005/DC1).
We conclude that the targeting of a vaccine protein to DCs
improves CD4+ T cell immunization relative to other approaches including DNA and recombinant adenovirus-gag
vaccines, which are currently undergoing testing in humans.
DC-targeted HIV gag protein induces broad CD4+
T cell immunity
To ensure that the DEC-205 targeting strategy could induce
immunity in different MHC haplotypes, we studied three
strains: BALB/c (H-2d), C57BL/6 (H-2b), and C3H (H-2k).
In each, 0.2–2% of the CD4+ T cells became responsive to
gag for at least two different p24 peptide pools (Fig. 4 A).
We are unable to find reports in the literature of CD4+ T cell
responses of this magnitude or breadth with other candidate
vaccines. When the reactive p24 pools were broken down into
individual peptides, at least two different mimetope peptides
were reliably recognized in each of the strains (Table II). We
also engineered the larger gag p41 protein into the anti–DEC205 heavy chain and showed that this protein in C57BL/6
mice broadened the immune response further to include a
third highly immunogenic peptide from the p17 portion of
gag (Fig. 4 B). When we used graded doses of these individual
peptides in the assay for T cell immunity, the mimetope peptides gave optimal responses with 0.1 μg/ml, which indicate
a good functional affinity of the T cells (Fig. 4 C, three separate experiments). Therefore, a single dose of HIV protein targeted to DCs results in a broad spectrum of peptides being
efficiently recognized by CD4+ T cells, features that should
reduce the chances of immune evasion by the virus.
JEM VOL. 203, March 20, 2006

Anti–DEC-p24 induces long-term memory CD4+ T cells
To test if long-term memory could be detected 19–30 wk after
priming, we measured CD4+ T cell proliferation by CFSE
dilution in response to antigen. Effector–memory cells were no
longer detected; i.e., T cells making IFN-γ within 6 h of antigen rechallenge. However, memory T cells responding by
proliferation to HIV gag were found in both BALB/c and
C57BL/6 mice immunized with a single dose of anti–DECp24 (Fig. 5, arrows), relative to the background responses seen
with no peptide and a nonreactive peptide pool from gag p17
(this background proliferation, termed the syngeneic mixed
leukocyte reaction, is observed when DCs are cocultured
with T cells in the absence of added antigens; reference 40). No
memory cells were observed after vaccination with control
Ig-p24 or with two injections of 50 μg of a gag p24 DNA
(Fig. 5, first and third rows). Therefore, long-term memory is
detected 4–7.5 mo after a single-dose DC-targeted HIV vaccine.
Anti–DEC-p24 elicits protective immunity
at a mucosal surface
To determine if immunity to gag p24 leads to protection,
especially at a mucosal surface distal to the skin vaccination site,

Table II. HIV gag p24 mimetope peptides identified from 15-mer
peptide pools to stimulate IFN-γ secretion by CD4+ T cells
in three MHC haplotypes after anti–DEC-p24 immunization
Strain
C3H
BALB/c
C57BL/6

HIV gag p24
Peptide pool

Reactive peptide

2
4
1
3
1
4

AAEWDRLHPVHAGPI (aa 209–223)
YSPTSILDIRQGPKE (aa 277–291)
SPEVIPMFSALSEGA (aa 165–179)
PVGEIYKRWIILGLN (aa 257–271)
QAISPRTLNAWVKVV (aa 145–159)
VDRFYKTLRAEQASQ (aa 297–311)

5 μg anti–DEC-p24 antibody in combination with 25 μg anti-CD40 and 50 μg poly
IC was administered either i.p. to BALB/c mice or s.c. to C57BL/6 or C3H mice as in
Fig. 4 A. After 17 d, splenic CD4+ T cells were restimulated with CD11c+ DCs and
single peptides from the different reactive HIV gag p24 peptide pools (2 μg/ml) for
2 d. IFN-γ secretion was evaluated by ELISPOT.
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BALB/c mice were immunized with a single dose of anti–DEC-205 or control Ig-gag p24 fusion antibody i.p. or the indicated dose of recombinant adenovirus gag vaccine i.m.
The mAb fusion vaccine was given together with poly IC and anti-CD40 mAb. 18 d later, the frequency of IFN-γ–producing CD4+ and CD8+ T cells was measured by
intracellular cytokine staining assay using the dominant peptide pools for these responses, pool 3 and pool 2, respectively. The underlined data contrasts the development of
strong CD4+ T cell immunity to anti–DEC-205 gag fusion mAb and CD8+ T cell immunity to recombinant adenovirus.

stimulus. IFN-γ secretion in spleen CD3+ T cells was measured at 15 d
in response to medium or different HIV gag p24 and p17 peptide pools.
Data shown are from one of three experiments. (C) In three experiments
C57BL/6 mice were vaccinated s.c. with 2 μg anti–DEC-p24 with maturation stimulus, and 19 d later, splenocytes were restimulated with graded
doses of HIV gag p24 peptide number 6 from pool 1 (QAISPRTLNAWVKVV,
p24 aa 145–159) or peptide number 8 from pool 4 (VDRFYKTLRAEQASQ,
p24 aa 297–311).

we challenged the mice with recombinant vaccinia-gag intranasally, first at 2 wk after vaccination. The mice lost weight and
developed high titers of virus in the lung over 7 d (>108 PFU/ml
of tissue). By both criteria, reduced weight loss (Fig. 6,
A, C, and E) and reduction in viral titers (Fig. 6, B, D, and F),
both BALB/c and C57BL/6 mice were protected by the
combination of anti–DEC-p24 plus a maturation stimulus,
but were not protected when immunized with anti–DECp24 alone, maturation stimulus alone, or control Ig-p24 plus
a maturation stimulus (Fig. 6, A and B). Vaccinated mice
were protected against recombinant vaccinia-gag but not vaccinia-OVA, indicating that protection was gag specific (not
depicted). We repeated the challenges but at longer time
points, 12 and 24 wk after one dose of vaccine. Again, the DCtargeted vaccine protected the mice from a serious infection
at a mucosal surface (not depicted). To evaluate the need for

IFN-γ in protection, we studied IFN-γR knockout mice.
The latter were not protected (Fig. 6, C and D), although the
knockout mice did generate CD4+ T cell immunity comparably
to wild-type mice (not depicted). Likewise, when we depleted
CD4+ T cells from vaccinated mice before the challenge
with vaccinia-gag, protection was ablated (Fig. 6, E and F) as
expected from prior work on CD4+ protection to vaccinia
(41). Because we were observing resistance at a mucosal surface
after s.c. injection of vaccine, we verified prior information
that anti–DEC-205 mAb is able to target systemically to DCs,
including DCs in lymphoid tissues that drain mucosal surfaces
(30). Specifically, we observed that p24 protein, when injected
as a fusion anti–DEC-205 mAb, was primarily targeted to the
CD8αhigh DC subset (which is also the DEChigh subset) in
the spleen and mesenteric lymph node (Fig. S3, available at
http://www.jem.org/cgi/content/full/jem.20052005/DC1).
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Figure 4. Breadth and strength of responses to DC-targeted HIV
gag vaccine. (A) 5 μg anti–DEC-p24 mAb in combination with maturation stimulus was administered either i.p. to BALB/c mice (top) or s.c. to
C57BL/6 (middle) and C3H (bottom) mice. 18 d later, IFN-γ secretion in
spleen CD3+ T cells was measured to medium or different HIV gag p24
peptide pools. Data are representative of two to four experiments with
two mice pooled in each experiment. (B) C57BL/6 mice were immunized
s.c. with 5 μg anti–DEC-p41 or control Ig-p41 mAbs and maturation

ARTICLE

labeled, and restimulated with CD11c+ DCs plus the peptide pools as indicated, anti-CD3 and anti-CD28, or medium. Proliferation was evaluated
by CFSE dilution at 4 d. Numbers are the percentage of CD4+ proliferating
T cells. Control PBS-immunized mice showed similar proliferative responses to control Ig-p24 mAb or two doses of DNA gag p24 vaccine.
Data are representative of two to three experiments on the same batch
of immunized mice.

Thus, IFN-γ–producing CD4+ T cells help to protect at
a mucosal surface, and this resistance follows one dose of
DC-targeted HIV gag fusion mAb vaccine.
DISCUSSION
Vaccine design has for some time depended on the discoveries
of Pasteur that attenuated and inactivated microorganisms can

induce specific and protective immunity (for review see references 11 and 42). It has been difficult to extend this strategy
to many global infections because attenuated and inactivated
vaccines are either difficult to produce, potentially unsafe,
or poorly immunogenic. As a result, alternative vaccines are
being tested, such as naked plasmid DNA and recombinant
modified vaccinia-Ankara and adenoviruses (37–39). Efforts

Figure 6. A single dose of anti–DEC-p24 vaccine elicits CD4dependent protection at a mucosal surface. (A and B) Groups of four to
six BALB/c or C57BL/6 mice were immunized as in Fig. 1 and challenged at
2–3 wk with 5 × 104 PFU of vaccinia-gag intranasally. Weight was measured for 6–7 d, and then lung virus titers were evaluated by plaque assay.
Data are representative of two experiments in BALB/c and one in C57BL/6.
(C and D) C57BL/6 or IFN-γR knockout mice were immunized s.c. with

2 μg anti–DEC-p24 with maturation stimulus or with PBS and challenged
with 2.5 × 104 PFU of vaccinia-gag 20 d later. (E and F) CD4+ T cells were
depleted from C57BL/6 immunized mice with three doses of anti-CD4 mAb
or control rat Ig 1–3 d before challenge. Data shown are one of three
similar experiments. Weights are expressed as average body weight,
whereas vaccinia plaque-forming titers (in CV-1 cells) are shown as a
mean ± SD.

JEM VOL. 203, March 20, 2006
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Figure 5. Long-lived gag p24-memory to DC-targeted vaccine.
BALB/c mice were immunized i.m. with two doses of 50 μg HIV gag p24
DNA or i.p. with 5 μg anti–DEC-p24 and control Ig-p24 mAb with maturation stimulus. C57BL/6 mice were similarly immunized, but the fusion
antibodies and maturation stimulus were given s.c. CD4+ T cells were
enriched by depleting MHC II+ and CD8+ cells from the lymph node
(30 wk after BALB/c immunization) or spleen (at 19 wk for C57BL/6), CFSE

614

latter study of antibody formation, we introduced a circumsporozoite protein from a malaria sporozoite into the anti–
DEC-205 mAb.
We noted that the DEC-targeted vaccine was superior in
inducing CD4+ T cell responses relative to unconjugated
protein with standard adjuvants, plasmid DNA, or recombinant adenovirus. Interestingly, the gag DNA vaccines we
prepared induced similar or better CD8+ T cell responses
when compared with low doses of anti–DEC-205 gag vaccine, but the CD4+ T cell response to DNA vaccine was
weak and lacked detectable memory (by a T cell proliferation
assay). Likewise, the recombinant adenovirus that we tested
induced strong CD8+ T cell responses but again much lower
numbers of IFN-γ–producing CD4+ T cells relative to anti–
DEC-gag vaccine. DNA vaccines are capable of inducing
some CD4+ T cell immunity in humans (44), but our data
from mice suggest that the efficiency and breadth of CD4+
T cell immunization can be increased substantially using
DC-targeted protein vaccines. It will be important to combine
anti–DEC-205 delivery with other modalities like plasmid
DNA and recombinant adenovirus because the improved
CD4+ T cell help from DEC-205 targeting could greatly improve the antibody and cytotoxic T cell immunity induced
by these other vaccines.
Another interesting consequence of the DEC-targeted
vaccine was that protective CD4+ T cell immunity was elicited at a mucosal surface, the airway, which was distal to the
skin vaccination site. This was observed in two mouse strains
that were tested, C57BL/6 and BALB/c. Previously, we had
noted that immunization of mice with anti–DEC-OVA allowed for protection to a challenge with vaccinia-OVA, but
we did not pursue long-term memory or the contribution of
CD4+ T cells and IFN-γ to protection (30). Our results at
first glance seemed surprising because there is evidence that
DCs capturing antigen from the skin immunize T cells with
skin-homing properties, whereas DCs capturing antigen in a
mucosal-associated lymphoid organ prime T cells that home
to the mucosa (45). We suspect that our observations reflect
the capacity of mAb targeting to load DCs with antigen in
lymph nodes that drain mucosal surfaces (Fig. S3; reference 30).
It is also somewhat surprising to detect a role for CD4+ T cells
in vaccinia protection because prior studies have demonstrated a role for CD8+ T cells in defense of mice against
vaccinia (46) or the pathogenic mouse pox, ectromelia virus
(47). Nevertheless, Xu et al. (41) reported CD4+ T cell–
dependent protection via antibody formation to vaccinia. It is
also possible that the strong CD4+ T cell responses induced
by DEC-205 targeting provides direct resistance, e.g., through
high level IFN-γ production and lysis of MHC class II–
bearing infected epithelial cells.
Given the normal tolerogenic function of at least some immature DCs in vivo in the steady-state (28, 29, 48, 49), a DC
maturation stimulus becomes an important component of a
vaccine. Here we have used a combination of agonistic antiCD40 mAb and poly IC, the latter to ligate TLR3 receptors
expressed by the DEC-205+ subset of DCs in mice (50).
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are underway to increase the immunogenicity of these safe
vaccines. We have been taking a different approach, which is
to develop protein-based vaccines that directly rely on principles of the immune system, to induce stronger T cell immunity and protection.
We are emphasizing DCs, which are pivotal cells for initiating adaptive immunity and memory, particularly T cell–
based responses. To better identify and harness the functions of
DCs in intact lymphoid tissues, antigens are delivered within
mAbs to specific DC receptors, beginning with a mAb to the
endocytic receptor DEC-205 or CD205. The DEC-205 target represents a beginning because the biological outcome
may be influenced by the specific DC receptor, the maturation stimulus used to allow DCs to elicit immunity, and the
subset of DCs expressing the receptor in question. Previously, we immunized mice with the model protein OVA
that was chemically (but not stoichiometrically) conjugated
to anti–DEC-205, and we studied the primary CD4+ T cell
response to a single previously defined MHC class II–binding
peptide in H-2b mice (30). Here we immunized mice of
different MHC haplotypes with a homogenous engineered
mAb carrying the HIV gag protein, and we studied the
breadth and quality of the CD4+ T cell response, including
memory and CD4-dependent protection at a mucosal surface. Our data reveal the potential of DCs in situ to elicit a
CD4+ T cell response of a quality and quantity that has not
been observed previously by other approaches to either study
DC function or to develop safe vaccines.
The quality of the CD4+ T cell response was indicated
first by its breadth; i.e., the development of immunity in all
three MHC haplotypes that were tested, including recognition of at least two gag peptides in each haplotype. This is
in contrast to most analyses of protein vaccination in mice,
which typically lead to immunization to a single peptide in
one haplotype. We used mimetope peptides derived from an
overlapping library of 15 mers spanning the full length of
the gag p41 protein rather than naturally processed peptides.
But even so, relatively low doses of the mimetope peptides
(0.1 μg/ml) were required to activate the population of primed
T cells in the immune assays. In addition, the observed responses were high even after a single dose of vaccine and included the induction of memory and CD4+ T cell–based
protection at a mucosal surface. We have emphasized a single
dose of vaccine because single episodes of certain infections
induce protective immunity, and it would be important to
mimic this and identify principles that quickly lead to strong
immunity with safe vaccines. The use of a single dose also
provides a means to compare the efficacy of individual vaccines for their capacity to induce a primary immune response
and ultimately memory. Additional research is required to
study memory and secondary responses after targeted delivery of antigens to DCs in situ. Nonetheless, booster responses
are evident, because in a companion paper in this issue
(p. 599), the priming of helper CD4+ T cells with anti-DEC
fusion mAbs sets the stage for a strong antibody response to
a boost with free antigen or anti-DEC fusion mAb (43). In this
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MATERIALS AND METHODS
Animals. We used C57BL/6 (B6), C3H, and BALB/c mice from Taconic,
IFN-γR knockouts (B6 background) from The Jackson Laboratory, and
DEC-205−/− mice made by us. Mice were maintained under specific pathogenfree conditions and used at 7–8 wk of age according to the guidelines of our
Institutional Animal Care and Use Committee.
Fusion HIV gag mAbs and other vaccines. DNA for HIV-1 gag p24 or
gag p41, i.e., aa 133–363 or aa 1–363 of gag p55 protein (from HIV isolate
BH10), was cloned in frame into the COOH terminus of anti–DEC-205
and control mAb heavy chains (28). Fusion mAbs were expressed by transient transfection (calcium-phosphate) in 293 cells in serum-free DMEM
supplemented with Nutridoma SP (Roche), purified on protein G columns
(GE Healthcare), and characterized by SDS-PAGE and Western blotting
(horseradish peroxidase sheep anti–mouse IgG [GE Healthcare] or α-p24
[ImmunoDiagnostics]). Unconjugated anti–DEC-205 mAb expressed by
stably transfected CHO cells was similarly purified. Plasmid DNA gag p24
vaccine was prepared by Aldevron. The plasmid was derived from consensus
B gag (HIV Databases), codon optimized to improve expression, and cloned
into the commercial plasmid pVAX1 (Invitrogen). The aa sequence encoding the DNA gag p24 vaccine differed from the p24 protein sequence derived from BH10 isolate at positions 138 (I→L) and 215 (V→L), respectively.
Vaccine DNA was eluted into saline at 1 μg/μl, and endotoxin in purified
DNA was <5 EU/mg. To construct a recombinant adenoviral vector vaccine, the consensus B gag p24 plasmid was cloned into a commercial E1/E3deleted, replication-incompetent adenoviral type 5 vector (BD Biosciences).
This vector was propagated in HEK 293 cells and purified according to the
manufacturer’s instructions (ViraKit for adenovirus 5; Virapur, LLC). Infectious units were determined by cytopathic effects and subsequent measurement
JEM VOL. 203, March 20, 2006

of HIV gag p24 by ELISA. One or two doses of 50 μg HIV-1 gag p24 DNA
or one dose of recombinant adenovirus (5 × 105 or 2 × 107 PFU) was
administered i.m.
Antigen targeting and maturation of DCs in vivo. Mice were injected
i.p. or s.c. in the hind footpads with fusion mAb, unconjugated anti-DEC
mAb, or HIV gag p41 protein (provided by R. Seder, National Institutes of
Health [NIH], Bethesda, MD) without or with a stimulus for DC maturation, which was 50 μg poly IC (InVivoGen) and 25 μg 1C10 agonistic
anti-CD40 mAb (54) per mouse.
HIV gag peptides. Overlapping (staggered by 4 aa) gag p17 and p24 15-mer
peptides were obtained from the NIH AIDS Reference Reagent Program
(catalog no. 8117). Peptides, including the H-2Kd binding peptide p24 197–
205 (36), were also synthesized by the Proteomics Resource Center (The
Rockefeller University). The 30- and 60-member gag p17 and p24 libraries
were divided into 3 and 5 pools of 9 to 12 peptides, respectively. The respective gag p17 peptide pools span from aa 1–51 (pool 1), aa 41–91 (pool 2), and
aa 81–135 (pool 3) of the HIV gag p17 protein, and the respective gag p24
peptide pools span from aa 125–183 (pool 1), aa 173–231 (pool 2), aa 221–
279 (pool 3), aa 269–327 (pool 4), and aa 317–363 (pool 5) of the HIV gag
p24 protein.
Assays for HIV gag-specific immune T cells. To identify HIV gagresponsive T cells, spleen cells were stimulated with pools of peptides (2 μg/ml)
or medium alone in the presence of 2 μg/ml of costimulatory anti-CD28
(clone 37.51) for 6 h, adding 10 μg/ml brefeldin A (Sigma-Aldrich) for the
last 4 h to accumulate intracellular cytokines. Cells were washed, incubated
for 15 min at 4°C with 2.4G2 mAb to block Fcγ receptors, and stained with
FITC- or PE-conjugated anti-CD3 (145-2C11) and PerCP-conjugated
anti-CD4 (RM4-5) or anti-CD8 (S3-6.7) for 20 min at 4°C. The cells were
permeabilized (Cytofix/Cytoperm Plus; BD Biosciences) and stained with
PE- or APC-anti–IFN-γ (XMG 1.2) and PE- or APC-anti–IL-2 (JESG5H4) mAbs for 15 min at room temperature (BD Biosciences). We used a
FACSCalibur with data analysis in FlowJo (Tree Star). All plots were gated
on low forward and side scatter CD3+ cells. For ELISPOT assays, we restimulated for 2 d CD4+ or CD8+ T cells, purified by positive selection,
with CD11c+ spleen DCs and HIV gag p24 peptide pools (2 μg/ml),
an H-2Kd–restricted peptide (2 μg/ml; AMQMLKETI, p24 197–205), or medium alone. DCs were enriched from the spleens or mesenteric lymph nodes
dissociated with collagenase (collagenase D; Roche) using anti-CD11c–
coated magnetic beads (Miltenyi Biotec). We used CFSE (107 cells/ml,
1 μM, 10 min, 37°C; Invitrogen) dilution to assess proliferation of primed
T cells in response to antigen. CD4+ T cells from the spleen or lymph node
were obtained by depleting MHC class II+ and CD8+ cells. After labeling
with CFSE, the T cells were added at 10–30 CD4+ T cells per spleen CD11c+ DC
in the presence of HIV gag p24 peptide pools (2 μg/ml), nonreactive peptide pool, medium alone, or anti-CD3 (0.1 μg/ml) and anti-CD28 (2 μg/ml;
positive control) for 4 d in 1 ml round-bottom tubes.
Antibody-mediated delivery of HIV gag p24 to DCs in lymphoid
tissues. CD11c+ DCs were enriched from lymphoid organs of mice given
10 μg anti–DEC-p24 or control Ig-p24 1 d earlier s.c. The cells were preincubated with 2.4G2 culture medium to block Fcγ receptors, washed, and incubated with PE-conjugated CD11c (HL3; BD Biosciences) and APC-conjugated
CD8 (53-6.7; BD Biosciences) for 20 min at 4°C. Permeabilized cells (Cytofix/
Cytoperm Plus) were stained with FITC–anti-p24 mAb (KC57-FITC;
Coulter) for 15 min at room temperature and evaluated by flow cytometry.
Protection experiments to an airway challenge with recombinant
vaccinia-gag. 2.5–5 × 104 PFU recombinant vaccinia-gag virus or vacciniaOVA control were applied intranasally to anesthetized mice (30, 55). In some
experiments, vaccinated B6 mice were depleted of CD4+ T cells by injection
with 500 μg GK 1.5 mAb 1–3 d before challenge. To assess protection, we
monitored body weights daily for 6–7 d, and then the animals were killed
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Interestingly, we did not observe a primary response to a single
dose of DEC-205–targeted vaccine when poly IC was the
only maturation stimulus, even though the DCs responded by
remodeling cell surface markers in a way that is characteristic
of DC maturation; i.e., increased expression of MHC class II
and CD86 and decreased expression of CD119 IFN-γ receptor (not depicted). It has been shown previously that these
changes in surface phenotype are not by themselves sufficient
to generate CD4+ and CD8+ T cell immunity by antigenpresenting DCs (51). However, poly IC did enhance the adjuvant effect of anti-CD40, as was also observed with tumor cell
antigens when they were targeted to DCs in situ (52). Further
research is needed to identify appropriate maturation stimuli
for DC-targeted vaccines, including DCs in humans and nonhuman primates, and these studies will need to include analyses of the induction of memory as well as more relevant
protection assays than the vaccinia-gag model used here.
At this point, we have targeted a single receptor, DEC205/CD205, which is expressed by a subset of CD8+ DCs.
Isolated and cultured CD8+ DCs produce IL-12 (17, 53), and
when loaded with antigen and reinfused into mice, these DCs
differentiate IFN-γ–producing T cells (21). Nonetheless, the
control of antigen access to DCs and the maturation of the
DCs in vivo represent intricate new areas of immunobiology.
Other DC receptors, DC subsets, and immune responses—
particularly memory—will be important to investigate.
DC-targeted vaccines offer potential advantages with respect
to safety and ease of production, and we suggest they should
be tested to improve efficacy as a stand-alone approach or in
combination with other modalities.

(because of considerable weight loss) and the lungs harvested to prepare extracts by physical disruption. Weight data are expressed as average body weight
from groups of four to six mice, whereas vaccinia titers in a plaque-forming
assay (in CV-1 cells) are shown as a mean ± SD for four to six mice.
Online supplemental material. Fig. S1 shows the constructs we prepared
to express fusion mAbs that carry HIV gag, as well as SDS-PAGE electrophoresis and immunoblot analysis of the control Ig-p24 and anti–DEC-p24
fusion mAbs. Fig. S2 shows that recombinant adenovirus-gag induces a strong
CD8+ T cell response, whereas anti–DEC-p24 elicits a robust CD4+ T cell
response. Fig. S3 shows the systemic distribution of p24 (in spleen and mesenteric lymph node, CD8α+ and DEC-205+ DCs) after anti–DEC-205 targeting
s.c. Figs. S1–S3 are available at http://www.jem.org/cgi/content/full/
jem.20052005/DC1.

Submitted: 6 October 2005
Accepted: 1 February 2006

REFERENCES
1. Seder, R.A., and J.R. Mascola. 2003. Basic immunology of vaccine
development. In The Vaccine Book. B.R. Bloom and P.-H. Lambert,
editors. Academic Press, Boston. 51–72 pp.
2. Berzofsky, J.A., J.D. Ahlers, J. Janik, J. Morris, S. Oh, M. Terabe, and
I.M. Belyakov. 2004. Progress on new vaccine strategies against chronic
viral infections. J. Clin. Invest. 114:450–462.
3. Pantaleo, G., and R.A. Koup. 2004. Correlates of immune protection
in HIV-1 infection: what we know, what we don’t know, what we
should know. Nat. Med. 10:806–810.
4. Saul, A., V. Nussenzweig, and R.S. Nussenzweig. 2004. Rationale for
malaria vaccine development. In Novel Vaccination Strategies. S.H.E.
Kaufmann, editor. Wiley-Vch Verlag GmbH & Co. 479–503.
5. Frazer, I.H. 2004. Prevention of cervical cancer through papillomavirus
vaccination. Nat. Rev. Immunol. 4:46–54.
6. Bevan, M.J. 2004. Helping the CD8+ T-cell response. Nat. Rev.
Immunol. 4:595–602.
7. Rosenberg, E.S., J.M. Billingsley, A.M. Caliendo, S.L. Boswell, P. Sax,
S.A. Kalams, and B.D. Walker. 1997. Vigorous HIV-1-specific CD4+ T
cell responses associated with control of viremia. Science. 278:1447–1450.
8. Martinez, V., D. Costagliola, O. Bonduelle, N. N’Go, A. Schruriger,
I. Theodorou, J.-P. Clauvel, D. Sicard, H. Agut, P. Debre, et al. 2005.
Combination of HIV-1-specific CD4 Th1 cell responses and IgG2
anitbodies is the best predictor for persistence of long-term nonprogression. J. Infect. Dis. 191:2053–2063.
9. Lichterfeld, M., D.E. Kaufmann, X.G. Yu, S.K. Mui, M.M. Addo,
M.N. Johnston, D. Cohen, G.K. Robbins, E. Pae, G. Alter, et al. 2004.
Loss of HIV-1–specific CD8+ T cell proliferation after acute HIV-1
infection and restoration by vaccine-induced HIV-1–specific CD4+ T
cells. J. Exp. Med. 200:701–712.
10. Kaech, S.M., E.J. Wherry, and R. Ahmed. 2002. Effector and memory
T-cell differentiation: implications for vaccine development. Nat. Rev.
Immunol. 2:251–262.
11. Levine, M.M., and M.B. Sztein. 2004. Vaccine development strategies
for improving immunization: the role of modern immunology. Nat.
Immunol. 5:460–464.
12. Steinman, R.M. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271–296.
13. Hart, D.N.J. 1997. Dendritic cells: unique leukocyte populations which
control the primary immune response. Blood. 90:3245–3287.
616

ANTI–DENDRITIC CELL HIV FUSION ANTIBODY VACCINE | Trumpfheller et al.

Downloaded from http://rupress.org/jem/article-pdf/203/3/607/1000072/607.pdf by Rockefeller University user on 14 August 2020

We thank S. Yamazaki and L. Munoz for their contribution to this work, H. Zebroski
for synthesizing peptides, and J. Adams for help with the graphics. Funding was
provided by NIH grants U19 AI062623 to T.M. Moran, RO1 AI41111 to C.B. Lopez,
and BM, AI13013 and AI40874 to R.M. Steinman, Direct Effect, as well as a
grant from the Foundation for the NIH through the Grand Challenges in Global
Health Initiative.
R.M. Steinman and M.C. Nussenzweig are consultants to Celldex, which is
developing human DEC-205–based vaccines.
All other authors do not have a conflict of interest.

14. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y.-J. Liu,
B. Pulendran, and K. Palucka. 2000. Immunobiology of dendritic cells.
Annu. Rev. Immunol. 18:767–811.
15. Lanzavecchia, A., and F. Sallusto. 2001. Regulation of T cell immunity
by dendritic cells. Cell. 106:263–266.
16. Moser, M. 2003. Dendritic cells in immunity and tolerance—do they
display opposite functions? Immunity. 19:5–8.
17. Pulendran, B. 2004. Modulating vaccine reponses with dendritic cells
and toll-like receptors. Immunol. Rev. 199:227–250.
18. Inaba, K., and R.M. Steinman. 1985. Protein-specific helper T lymphocyte formation initiated by dendritic cells. Science. 229:475–479.
19. Inaba, K., J.P. Metlay, M.T. Crowley, and R.M. Steinman. 1990.
Dendritic cells pulsed with protein antigens in vitro can prime antigenspecific, MHC-restricted T cells in situ. J. Exp. Med. 172:631–640.
20. Schuler-Thurner, B., E.S. Schultz, T.G. Berger, G. Weinlich, S. Ebner,
P. Woerl, A. Bender, B. Feuerstein, P.O. Fritsch, N. Romani, and
G. Schuler. 2002. Rapid induction of tumor-specific type 1 T helper cells
in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med.
195:1279–1288.
21. Maldonado-Lopez, R., T. De Smedt, P. Michel, J. Godfroid, B. Pajak,
C. Heirman, K. Thielemans, O. Leo, J. Urbain, and M. Moser. 1999.
CD8α+ and CD8α− subclasses of dendritic cells direct the development
of distinct T helper cells in vivo. J. Exp. Med. 189:587–592.
22. Jiang, W., W.J. Swiggard, C. Heufler, M. Peng, A. Mirza, R.M.
Steinman, and M.C. Nussenzweig. 1995. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature. 375:151–155.
23. Mahnke, K., M. Guo, S. Lee, H. Sepulveda, S.L. Swain, M.
Nussenzweig, and R.M. Steinman. 2000. The dendritic cell receptor
for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II–positive lysosomal
compartments. J. Cell Biol. 151:673–683.
24. Kraal, G., M. Breel, M. Janse, and G. Bruin. 1986. Langerhans cells,
veiled cells, and interdigitating cells in the mouse recognized by a monoclonal antibody. J. Exp. Med. 163:981–997.
25. Vremec, D., and K. Shortman. 1997. Dendritic cell subtypes in mouse
lymphoid organs. Cross-correlation of surface markers, changes with
incubation, and differences among thymus, spleen, and lymph nodes.
J. Immunol. 159:565–573.
26. Inaba, K., W.J. Swiggard, M. Inaba, J. Meltzer, A. Mirza, T. Sasagawa,
M.C. Nussenzweig, and R.M. Steinman. 1995. Tissue distribution
of the DEC-205 protein that is detected by the monoclonal antibody
NLDC-145. I. Expression on dendritic cells and other subsets of mouse
leukocytes. Cell. Immunol. 163:148–156.
27. Witmer-Pack, M.D., W.J. Swiggard, A. Mirza, K. Inaba, and R.M.
Steinman. 1995. Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. II. Expression in situ in
lymphoid and nonlymphoid tissues. Cell. Immunol. 163:157–162.
28. Hawiger, D., K. Inaba, Y. Dorsett, K. Guo, K. Mahnke, M. Rivera,
J.V. Ravetch, R.M. Steinman, and M.C. Nussenzweig. 2001. Dendritic
cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194:769–780.
29. Bonifaz, L., D. Bonnyay, K. Mahnke, M. Rivera, M.C. Nussenzweig,
and R.M. Steinman. 2002. Efficient targeting of protein antigen to the
dendritic cell receptor DEC-205 in the steady state leads to antigen
presentation on major histocompatibility complex class I products and
peripheral CD8+ T cell tolerance. J. Exp. Med. 196:1627–1638.
30. Bonifaz, L.C., D.P. Bonnyay, A. Charalambous, D.I. Darguste, S.
Fujii, H. Soares, M.K. Brimnes, B. Moltedo, T.M. Moran, and R.M.
Steinman. 2004. In vivo targeting of antigens to the DEC-205 receptor
on maturing dendritic cells improves T cell vaccination. J. Exp. Med.
199:815–824.
31. Hawiger, D., R.F. Masilamani, E. Bettelli, V.K. Kuchroo, and M.C.
Nussenzweig. 2004. Immunological unresponsiveness characterized by
increased expression of CD5 on peripheral T cells induced by dendritic
cells in vivo. Immunity. 20:695–705.
32. Trombetta, E.S., and I. Mellman. 2005. Cell biology of antigen processing in vitro and in vivo. Annu. Rev. Immunol. 23:975–1028.

ARTICLE

JEM VOL. 203, March 20, 2006

45.

46.

47.

48.

49.

50.

51.

52.

53.
54.

55.

boosted by recombinant modified vaccinia virus Ankara in humans.
Nat. Med. 9:729–735.
Mora, J.R., G. Cheng, D. Picarella, M. Briskin, N. Buchanan, and
U.H. von Andrian. 2005. Reciprocal and dynamic control of CD8 T
cell homing by dendritic cells from skin- and gut-associated lymphoid
tissues. J. Exp. Med. 201:303–316.
Bachmann, M.F., P. Wolint, K. Schwarz, and A. Oxenius. 2005. Recall
proliferation potential of memory CD8+ T cells and antiviral protection. J. Immunol. 175:4677–4685.
Fang, M., and L.J. Sigal. 2005. Antibodies and CD8+ T cells are complementary and essential for natural resistance to a highly lethal cytopathic virus. J. Immunol. 175:6829–6836.
Probst, H.C., J. Lagnel, G. Kollias, and M. van den Broek. 2003.
Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. Immunity. 18:713–720.
Probst, H.C., K. McCoy, T. Okazaki, T. Honjo, and M. van den
Broek. 2005. Resting dendritic cells induce peripheral CD8+ T cell
tolerance through PD-1 and CTLA-4. Nat. Immunol. 6:280–286.
Schulz, O., S.S. Diebold, M. Chen, T.I. Naslund, M.A. Nolte,
L. Alexopoulou, Y.T. Azuma, R.A. Flavell, P. Liljestrom, and C. Reis e
Sousa. 2005. Toll-like receptor 3 promotes cross-priming to virusinfected cells. Nature. 433:887–892.
Fujii, S., K. Liu, C. Smith, A.J. Bonito, and R.M. Steinman. 2004.
The linkage of innate to adaptive immunity via maturing dendritic cells
in vivo requires CD40 ligation in addition to antigen presentation and
CD80/86 costimulation. J. Exp. Med. 199:1607–1618.
Liu, K., J. Idoyaga, A. Charalambous, S. Fujii, A. Bonito, J. Mordoh,
R. Wainstok, X.F. Bai, Y. Liu, and R.M. Steinman. 2005. Innate NKT
lymphocytes confer superior adaptive immunity via tumor-capturing
dendritic cells. J. Exp. Med. 202:1507–1516.
Moser, M., and K.M. Murphy. 2000. Dendritic cell regulation of Th1Th2 development. Nat. Immunol. 1:199–205.
Heath, A.W., W.W. Wu, and M.C. Howard. 1994. Monoclonal antibodies to murine CD40 define two distinct functional epitopes. Eur.
J. Immunol. 24:1828–1834.
Brimnes, M.K., L. Bonifaz, R.M. Steinman, and T.M. Moran. 2003.
Influenza virus–induced dendritic cell maturation is associated with the
induction of strong T cell immunity to a coadministered, normally nonimmunogenic protein. J. Exp. Med. 198:133–144.

617

Downloaded from http://rupress.org/jem/article-pdf/203/3/607/1000072/607.pdf by Rockefeller University user on 14 August 2020

33. Ahonen, C.L., C.L. Doxsee, S.M. McGurran, T.R. Riter, W.F. Wade,
R.J. Barth, J.P. Vasilakos, R.J. Noelle, and R.M. Kedl. 2004. Combined
TLR and CD40 triggering induces potent CD8+ T cell expansion with
variable dependence on type I IFN. J. Exp. Med. 199:775–784.
34. Kern, F., N. Faulhaber, C. Frommel, E. Khatamzas, S. Prosch,
C. Schonemann, I. Kretzschmar, R. Volkmer-Engert, H.D. Volk, and
P. Reinke. 2000. Analysis of CD8 T cell reactivity to cytomegalovirus
using protein-spanning pools of overlapping pentadecapeptides. Eur.
J. Immunol. 30:1676–1682.
35. Maecker, H.T., H.S. Dunn, M.A. Suni, E. Khatamzas, C.J. Pitcher,
T. Bunde, N. Persaud, W. Trigona, T.-M. Fu, E. Sinclair, et al. 2001. Use
of overlapping peptide mixtures as antigens for cytokine flow cytometry. J. Immunol. Methods. 255:27–40.
36. Mata, M., P.J. Travers, Q. Liu, F.R. Frankel, and Y. Paterson. 1998.
The MHC class I-restricted immune response to HIV-gag in BALB/c
mice selects a single epitope that does not have a predictable MHCbinding motif and binds to Kd through interactions between a glutamine at P3 and pocket D. J. Immunol. 161:2985–2993.
37. McMichael, A.J., and T. Hanke. 2003. HIV vaccines 1983-2003. Nat.
Med. 9:874–880.
38. Emini, E.A., and W.C. Koff. 2004. AIDS/HIV. Developing an AIDS
vaccine: need, uncertainty, hope. Science. 304:1913–1914.
39. Donnelly, J.J., B. Wahren, and M.A. Liu. 2005. DNA vaccines: progress
and challenges. J. Immunol. 175:633–639.
40. Nussenzweig, M.C., and R.M. Steinman. 1980. Contributions of dendritic cells to stimulation of the murine syngeneic mixed leukocyte reaction. J. Exp. Med. 151:1196–1212.
41. Xu, R., A.J. Johnson, D. Liggitt, and M.J. Bevan. 2004. Cellular and
humoral immunity against vaccinia virus infection of mice. J. Immunol.
172:6265–6271.
42. Dubos, R. 1988. Pasteur and Modern Science. Science Tech Publishers,
Madison, WI. 168 pp.
43. Boscardin, S.B., J.C.R. Hafalla, R.F. Masilamani, A.O. Kamphorst, H.A.
Zebroski, U. Rai, A. Morrot, F. Zavala, R.M. Steinman, R.S. Nussenzweig,
and M.C. Nussenzweig. 2005. Antigen targeting to dendritic cells elicits
long-lived T cell help for antibody responses. J. Exp. Med. 203:599–600.
44. McConkey, S.J., W.H. Reece, V.S. Moorthy, D. Webster, S. Dunachie,
G. Butcher, J.M. Vuola, T.J. Blanchard, P. Gothard, K. Watkins, et al.
2003. Enhanced T-cell immunogenicity of plasmid DNA vaccines

